Overview

HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.
Phase:
Phase 4
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Rosuvastatin Calcium
Telmisartan